The CCR2 antagonist, combined with low-dose sorafenib, potentiated anti-liver tumor effects via upregulating intratumoral CD8+ T cells and enhanced the distribution of CD8+ T cells in the tumor milieu, without obvious toxicity [147]. Here, CCR2 is linked to neoplasm.